123 related articles for article (PubMed ID: 6786322)
21. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
Smith MP; Spence KJ; Waters EL; Beresford-Webb R; Mitchell MJ; Cuttler J; Alhaq A; Brown SA; Savidge GF
Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
[TBL] [Abstract][Full Text] [Related]
22. Freeze dried cryoprecipitate and home therapy.
Gabra GS; Mitchell R
J Clin Pathol; 1983 Nov; 36(11):1321-2. PubMed ID: 6415129
[No Abstract] [Full Text] [Related]
23. Home treatment of haemophilia. A follow-up study.
Ekert H; Moorehead M; Williamson G
Med J Aust; 1981 Jul; 2(1):21-3. PubMed ID: 6792476
[TBL] [Abstract][Full Text] [Related]
24. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
25. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
Klukowska A; Zieleniewska B
Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
[TBL] [Abstract][Full Text] [Related]
26. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
27. Thawed cryoprecipitate stored for 6 h at room temperature: a potential alternative to factor VIII concentrate for continuous infusion.
Pesquera-Lepatan LM; Hernandez FG; Lim RD; Chua MN
Haemophilia; 2004 Nov; 10(6):684-8. PubMed ID: 15569162
[TBL] [Abstract][Full Text] [Related]
28. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
[No Abstract] [Full Text] [Related]
29. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
30. Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia A.
Martinowitz U; Lalezari S; Luboshitz J; Lubetsky A; Spira J
Haemophilia; 2008 Sep; 14(5):1122-4. PubMed ID: 18564190
[No Abstract] [Full Text] [Related]
31. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
32. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
[TBL] [Abstract][Full Text] [Related]
33. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
[TBL] [Abstract][Full Text] [Related]
34. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
35. Specific therapy in haemophilia A--past and present.
Majer P; Procházka J
Acta Univ Palacki Olomuc Fac Med; 1983; 105():215-21. PubMed ID: 6229146
[No Abstract] [Full Text] [Related]
36. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
[TBL] [Abstract][Full Text] [Related]
37. Successful surgery in severe haemophilia--a two-stage replacement therapy in resource-poor countries.
Prabhu R; Jijina F; Shetty S; Ghosh K
Haemophilia; 2008 Sep; 14(5):1125-6. PubMed ID: 18625030
[No Abstract] [Full Text] [Related]
38. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
39. Practice patterns in haemophilia A therapy -- global progress towards optimal care.
Geraghty S; Dunkley T; Harrington C; Lindvall K; Maahs J; Sek J
Haemophilia; 2006 Jan; 12(1):75-81. PubMed ID: 16409179
[TBL] [Abstract][Full Text] [Related]
40. Letter: Factor-VIII concentrate in haemophilia.
Tamagnini GP; Dormandy KM; Ellis D; Maycock W
Lancet; 1975 Jul; 2(7926):188. PubMed ID: 49787
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
